[updated November 11, 1999]

 
 

RH for primary events in the first, second and third 4 month periods during the first year of HERS


 
Treatment Group

Time since randomization
Estrogen-Progestin (n=1380)
Placebo
(n=1383)
RH
P Value for trend
0 to 4 months
16
7
2.29
0.33
4 to 8 months
26
18
1.46
8 to 12 months
15
13
1.18


These results were originally reported in the subsection Primary CHD Outcome on page 608 of the JAMA article.